Clinical Trial Update: IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/2 trial evaluating the IN10018 combination therapy for advanced EGFR mutation-positive non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IN10018

Snippet

Sponsor: InxMed (Shanghai) Co., Ltd. | Conditions: NSCLC | Phase 1, Phase 2 | Status: RECRUITING